ǰÑÔ
ǰÏßÏÙ°©(prostate carcinomas)ÊÇÄÐÐÔÃÚÄòÉúֳϵͳ×î³£¼ûµÄÖ×Áö£¬¾ßÓв¡ÒòÖØ´ó¡¢·¢²¡²¿Î»Òþ²Ø¡¢Ç±ÔÚÆÚ³¤ÇÒ²¡ÀíÌåÏÖ¶àÑùµÈÌØµã¡£ÔÚÃÀ¹ú£¬Æä·¢²¡ÂÊÔÚÖ×Áö»¼ÕßÖÐÕ¼µÚ1룬éæÃüÂÊÕ¼µÚ2λ¡£ÎÒ¹úÉÐÎÞǰÏßÏÙ°©·¢²¡ÂʺÍéæÃüÂʵÄ׼ȷͳ¼Æ×ÊÁÏ£¬ËäԶȱ·¦Î÷Å·£¬µ«Ëæ×ÅÎÒ¹úÉú³ÝÀÏÁ仯ºÍÒûʳ½á¹¹µÄ¸Ä±ä£¬Ç°ÏßÏÙ°©·¢²¡ÂÊÓÐÖðÄêÔö¸ßµÄÇ÷ÊÆ£¬ÇÒ³õÕïʱÒÑÓÐ30%~50£¥Ç°ÏßÏÙ°©»¼Õß±¬·¢×ªÒÆ¡£Òò´Ë£¬¶ÔǰÏßÏÙ°©µÄÑо¿¾ßÓкÜÊÇÖ÷ÒªµÄÒâÒå¡£¶¯ÎïÄ£×ÓÊǽøÒ»²½Ñо¿Ç°ÏßÏÙ°©µÄ·¢²¡»úÖÆ¡¢Ö×ÁöÓëËÞÖ÷µÄ¹ØÏµ¡¢Ö×ÁöÇÖÏ®Óë×ªÒÆÀú³ÌºÍÖÎÁƲ½·¥ÓÐÓÃÐÔµÄÖ÷Òª¹¤¾ß¡£ÏÖÔÚ£¬Æ¾Ö¤Ç°ÏßÏÙ°©¶¯ÎïÄ£×Ó½¨ÉèµÄÒªÁìÌØµã¿É·ÖΪ×Ô¾õºÍÓÕ·¢Ä£×Ó¡¢ÒÆÖ²ÐÔÄ£×Ó¡¢»ùÒòÐÞÊÎÄ£×ӵȡ£Ö÷Òª¶¯ÎïÖÖÀàÊÇ´óÊó¡¢Ð¡ÊóºÍÈ®£¬½üÄêÀ´£¬ÒÅ´«¹¤³ÌСÊóÄ£×ÓÉú³¤ºÜ¿ì¡£
²¿·ÖÔìÄ£ÒªÁì
ʹÓö¯Î´óÊó
¡¾ÔìÄ£»úÖÆ¡¿£º
»¯Ñ§Ö°©¼ÁDMAB»®·ÖÓ볤Ч±ûËáØºÍª(testosterone propionate,TP)ÍŽáÓÕµ¼µÄǰÏßÏÙ°©Ä£×Ó·¢²¡Âʽϸߣ¬°©ÖׯðÔ´ÓÚ±³²àÒ¶¡¢ÖÐÒ¶£¬ÓëÈËǰÏßÏÙ°©ÓÐͬԴÐÔ¡£
¡¾ÔìÄ£ÒªÁì¡¿£º
1.6ÖÜÁäF344ÐÛÐÔ´óÊó,DMAB,TP¡£
2.´óÊó¸ôÖÜÆ¤ÏÂ×¢ÉäÒ»´ÎDMAB 50mg/kg£¬¹²20ÖÜ¡£Í¬Ê±Æ¤Ï°üÂñº¬ÓÐ40mg TPµÄ¹è½º¹Ü£¬¹²60ÖÜ£¬Ã¿6ÖÜ»»¹ÜÒ»´Î¡£
3.Ä£×Ó¼ì²â ¢ÙѪҺÖÐÐÛ¼¤ËØË®Æ½¼°ËáÐÔÁ×Ëáø»îÐÔ£ºÓÃÓÚÑо¿ØºÍª¶ÔǰÏßÏÙ°©±¬·¢µÄ×÷Óü°Ç°ÏßÏÙ°©µÄ¼ì²âÖ¸±ê£»¢ÚÒÅÌåÆÊ½â£º×Ðϸ¼ì²é¹Ç¡¢·Î¡¢¸ÎµÈ´¦ÓÐÎÞ×ªÒÆÔǰÏßÏÙ¸÷Ò¶ÄÚÖ×Áö±¬·¢ÇéÐΣ»¢Û²¿·Ö´óÊó¿ÉÄܱ¬·¢¶ñÐÔÏËά×é֯ϸ°ûÁö£¬ÓÐʱ¿ÉÖ´óÊóéæÃü£¬ÆÊ½âÊ±Òª×¢ÖØÇ°ÏßÏÙ¸÷Ò¶ÄÚÖ×ÁöµÄ±¬·¢ÇéÐΣ»¢ÜʯÀ¯°üÂñ¡¢²¡ÀíÇÐÆ¬¼ì²é¸÷Ò¶ÄÚǰÏßÏÙ¼°ÆäËûÔàÆ÷¿ÉÒɲ¡Ôî¡£
¡¾Ä£×ÓÌØµã¡¿£º
°©ÖׯðÔ´ÓÚ±³²àÒ¶¡¢ÖÐÒ¶£¬ÓëÈËǰÏßÏÙ°©ÓÐͬԴÐÔ£¬Ò²¾ßÓÐͨ¹ýѪµÀ¡¢Áܰ͵À×ªÒÆ¼°ÑªÇåËáÐÔÁ×ËáøÉý¸ßµÈÌØµã£¬ÇÒ²¡ÀíÀú³ÌÓë×éÖ¯·Ö½âÌØµãÓëÈËÏàËÆ£¬Òò¶ø±»ÒÔΪÊǽÏÁ¿ÀíÏëµÄÓÕ·¢ÐÔ¶¯ÎïÄ£×Ó¡£
¡¾Ä£×ӵįÀ¹ÀºÍÓ¦Óá¿£º
½«Ô·¢µÄ´óÊó¼¤ËØÇ°ÏßÏÙ°©×é֯ݪֲµ½ÂãÊó±³²¿Æ¤Ï¡£½¨ÉèÁËݪֲÐÔǰÏßÏÙ°©¶¯ÎïÄ£×Ó¡£½¨ÉèµÄݪֲÖ×ÁöÉú³¤Ñ¸ËÙ¡¢¾ßÓнϸß×ªÒÆÄÜÁ¦£¬ÓÈÆäÊÇÒ×±¬·¢·Î×ªÒÆ¡£¸ÃÖ×ÁöÖÆ×÷ʱ¼ä¶ÌÒ×ÓÚÊӲ죬¿ÉÓÃÓÚǰÏßÏÙ°©½þÈó¡¢×ªÒƺͼ¤ËØÒÀÀµÐÔµÄÑо¿¡£
²Î¿¼ÎÄÏ×£º
1.ÐìºèÐ÷£¬ÍõÏþ²¨£¬³ÂÁèÎä. ºÉÈËǰÏßÏÙ°©ÂãÊóÒÆÖ²ÁöÄ£×ӵĽ¨Éè¼°ÆäÓ¦ÓÃÑо¿£®ÊÊÓð©Ö¢ÔÓÖ¾£¬2006,21(4):337-350
2.ÏôÔÆ±¸£¬ÕÅÏþÍþ£¬Å£ÒÙ¶«£¬µÈ£®Ç°ÏßÏÙ°©¶¯ÎïÄ£×ÓʵÑ鶯Îï¿ÆÑ§£¬2010, 27 (6):55-58
3.´ÞÁÖ£¬¹ØÖ¾³À£®ÝªÖ²ÐÔÐÛ¼¤ËØ·ÇÒÀÀµÐÍǰÏßÏÙ°©¶¯ÎïÄ£×ӵĽ¨Éè. ÖлªÃÚÄòÍâ¿ÆÔÓÖ¾£¬2006,27(Suppl 2):39-41
4.¶ÀÚ£¬ÕÅÏþÅô£¬Ò×ÉÜÇí£¬µÈ£®±í´ïÈËǰÏßÏÙ¸Éϸ°û¿¹ÔСÊóǰÏßÏÙ°©Ä£×ӵĽ¨ÉèÖйúʵÑ鶯Îïѧ±¨£¬2009, 17(6):428-431
5.Gingrich JR, Barrios RJ, Morton RA, el al. Metastatic prostate cancer in a transgenic mouse. Cancer Res, 1996, 56 (18):4096-4102
6.Ittmann M, Huang J, Radaelli E, el al. Animal models of human prostate cancer:the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee, Cancer Res, 2013, 73 (9):2718-2736
7.Jones LW,Antonelli J,Masko EM,et al. Exercise modulation of the host-tumor interaction in an ortholop1c model of murine prostate cancer. J Appl Physiol (1985), 2012, 113 (2):263-272
8.Klyushnenkova EN, Kouiavskaia DV,Parkins CJ, et al. A cytomegalovirus-based vaccine expressing a single tumor specific CD8+ T-cell epitope delays tumor growth in a murine model of prostate cancer. J lmmunother,2012,35 (5):390-399
9.Shen L, Ciesielski M, Ramakrishnan S, el al.Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models. PLoS One, 2012, 7 (1): e30815
10.Shibata MA,Jorcyk CL.Liu ML,et al. The C3(1)/ SV40 T antigen transgenic mouse model of prostate and mammary cancer. Toxicol Pathol, 1998, 26 (1): 177-182
11.Shirai T,Imaida K,Iwasaki S,et al. Sequential observation of rat prostate lesion development induced by 3, 2'-dimelhyl-4-aminobiphenyl and testosterone. Jpn J Cance.r Res, 1993, 84 (1):20-25
12.Shirai T, Takahashi S, Cui L, et al. Experimental prostate carcinogenesis-rodent models. Mutat Res, 2000, 462 (2-3):219-226
13.Wang X, An Z, Geller J,et al. High-malignancy orthotopic nude mouse model of human prostate cancer LNCaP.Prostate, 1999,39(3): 182-186